The authors would like to thank Pr. B. Namour, Dr. R.-M. Gueant-Rodriguez and Dr. A. Oussalah for their critical review of this manuscript and S. Thirion for her excellent technical assistance (Laboratory of Biochemistry, Hospital of Nancy-Brabois, France).
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Ethical approval: The patients are all included in the NADIS® cohort, a dynamic French cohort of HIV-infected patients, after receiving verbal information and giving written consent. The collected data and details of the networking organization have been submitted to the French National Commission on Informatics and Rights (CNIL). All patients provide written informed consent prior to the inclusion of their data in the EMR. All merged data for analysis are therefore anonymous.
Guarantor of the article: Isabelle Aimone-Gastin, MD, PhD.
Authors’ contributions: IAG conceived the study. IAG and AL researched literature and analyzed the data. AL and FB were involved in the protocol development and CR was involved in the patients’ recruitment. AL wrote the first draft of the manuscript. All authors reviewed, edited and approved the final version of the manuscript.
References
1. Schmid H, Mühlbayer D, Röling J, Sternfeld T, Jülg B, Schlattner U, et al. Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK. Antivir Ther 2006;11:1071–80.10.1177/135965350601100813Search in Google Scholar
2. Gherardi RK. Skeletal muscle involvement in HIV-infected patients. Neuropathol Appl Neurobiol 1994;20:232–7.10.1111/j.1365-2990.1994.tb00964.xSearch in Google Scholar PubMed
3. Lee KN, Csako G, Bernhardt P, Elin RJ. Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem 1994;40:1278–83.10.1093/clinchem/40.7.1278Search in Google Scholar PubMed
4. Pugliese P, Cuzin L, Cabié A, Poizot-Martin I, Allavena C, Duvivier C, et al. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med 2009;10:504–11.10.1111/j.1468-1293.2009.00719.xSearch in Google Scholar PubMed
5. Remaley AT, Wilding P. Macroenzymes: biochemical characterization, clinical significance, and laboratory detection. Clin Chem 1989;35:2261–70.10.1093/clinchem/35.12.2261Search in Google Scholar PubMed
6. Laureys M, Sion JP, Slabbynck H, Steenssens L, Cobbaert C, Derde MP, et al. Macromolecular creatin kinase type 1: a serum marker associated with disease. Clin Chem 1991;37:430–4.10.1093/clinchem/37.3.430Search in Google Scholar
7. Watanabe D, Yoshino M, Yagura H, Hirota K, Yonemoto H, Bando H, et al. Increase in serum mitochondrial creatine kinase levels induced by tenofovir administration. J Infect Chemother 2012. DOI: 10.1007/s10156-012-0393-8) (PubMed).10.1007/s10156-012-0393-8)(PubMed)http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000310813100009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar
8. Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther 2002;24:1515–48.10.1016/S0149-2918(02)80058-3Search in Google Scholar PubMed
9. Shere-Wolfe KD, Verley JR. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir. Clin Infect Dis 2002;35:1137.10.1086/343747Search in Google Scholar PubMed
10. Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, Russ R, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009;89:513–9.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000265576000003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1038/labinvest.2009.14Search in Google Scholar PubMed PubMed Central
©2013 by Walter de Gruyter Berlin Boston
